PK Driven Prophylaxis for Hemophilia A

NCT ID: NCT02634424

Last Updated: 2020-03-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-25

Study Completion Date

2016-05-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the implementation of pharmacokinetic (PK) driven prophylaxis in current clinical practice

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Starting from 3 pharmacokinetic (PK) points, data are entered in the PK calculator device, and treatment dose is adjusted following the results of PK values obtained and clinical bleeding data

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia A

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MyPKFiT

Personalized prophylaxis : Treatment is adjustment according to PK modeling

Group Type EXPERIMENTAL

MyPKFiT

Intervention Type DEVICE

Adjustment of the treatment dose using a decision support software according to the PK values

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MyPKFiT

Adjustment of the treatment dose using a decision support software according to the PK values

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Personalized prophylaxis by PK modeling

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male Patient
* Severe or moderately severe haemophilia A (FVIII = 2 %), preventively treated (processing) by ADVATE for at least 6 months,
* At last 6 years old,
* An informed consent must be signed by the patient or his legal representative for the patients minor.
* Affiliated to a national insurance scheme

Exclusion Criteria

* Previous or actual treatment with FVIII inhibitors \> 0,6 UB at the selection
* Induction of immune tolerance
* Planned orthopedic surgery for the 18 next months
* Any other haemostatic pathology
* Any treatment interacting on the haemostasis
* Patient under guardianship
* Patient participating in another biomedical research
Minimum Eligible Age

6 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Baxter Healthcare Corporation

INDUSTRY

Sponsor Role collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thierry LAMBERT, MD

Role: PRINCIPAL_INVESTIGATOR

AP-HP, Bicêtre Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AP-HP, Bicêtre Hospital

Le Kremlin-Bicêtre, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P140701

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Factor IX Gene Therapy Study (FIX-GT)
NCT03369444 TERMINATED PHASE1/PHASE2
A Gene Therapy Study for Hemophilia B
NCT02484092 COMPLETED PHASE2
BAX 855 Continuation
NCT01945593 COMPLETED PHASE3